Lipoic acid improves survival in transgenic mouse models of Huntington's disease

被引：87
|
作者：
Andreassen, OA
Ferrante, RJ
Dedeoglu, A
Beal, MF
机构：
[1] Cornell Univ, Weill Med Coll, New York Hosp, Cornell Med Ctr,Dept Neurol & Neurosci, New York, NY 10021 USA
[2] Massachusetts Gen Hosp, Neurol Serv, Neurochem Lab, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Bedford VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bedford, MA USA
[5] Boston Univ, Sch Med, Boston, MA 02118 USA
来源：
NEUROREPORT | 2001年 / 12卷 / 15期
关键词：
antioxidants; excitotoxicity; Huntington's disease; alpha-lipoic acid; transgenic mice;
D O I：
10.1097/00001756-200110290-00044
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
There is substantial evidence implicating excitotoxicity and oxidative damage in the pathogenesis of Huntington's disease (HD). We therefore examined whether the antioxidants 2-sulpho-tert-phenylbutyinitrone (S-PBN) and alpha -lipoic acid could exert neuroprotective effects in transgenic mouse models of HD. S-PBN showed no effects on either weight loss or survival in the R6/2 transgenic HD mice. alpha -Lipoic acid produced significant increases in survival in both R6/2 and N171-82Q transgenic mouse models of HD. These findings suggest that alpha -lipoic acid might have beneficial effects in HD patients. NeuroReport 12:3371-3373 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码：3371 / 3373
页数：3
相关论文
共 50 条
  • [1] Transgenic mouse models for Huntington's disease.
    Reddy, PH
    Williams, M
    Miller, G
    Glass, M
    Paylor, R
    Garrett, L
    Herkenham, M
    Crawley, J
    Tagle, DA
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A52 - A52
  • [2] Transgenic Mouse Models of Parkinson's Disease and Huntington's Disease
    Skaper, Stephen D.
    Giusti, Pietro
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (04) : 455 - 470
  • [3] "Brain training" improves cognitive performance and survival in a transgenic mouse model of Huntington's disease
    Wood, Nigel I.
    Glynn, Dervila
    Morton, A. Jennifer
    [J]. NEUROBIOLOGY OF DISEASE, 2011, 42 (03) : 427 - 437
  • [4] Experimental therapeutics in transgenic mouse models of Huntington's disease
    Beal, MF
    Ferrante, RJ
    [J]. NATURE REVIEWS NEUROSCIENCE, 2004, 5 (05) : 373 - 384
  • [5] Experimental therapeutics in transgenic mouse models of Huntington's disease
    M. Flint Beal
    Robert J. Ferrante
    [J]. Nature Reviews Neuroscience, 2004, 5 : 373 - 384
  • [6] Valproate increases the survival in a transgenic mouse model of Huntington's disease
    Klivenyi, P.
    Zadori, D.
    Geisz, A.
    Vamos, E.
    Vecsei, L.
    [J]. MOVEMENT DISORDERS, 2010, 25 (07) : S273 - S273
  • [7] Transgenic models of Huntington's disease
    Bates, GP
    Mangiarini, L
    Mahal, A
    Davies, SW
    [J]. HUMAN MOLECULAR GENETICS, 1997, 6 (10) : 1633 - 1637
  • [8] Transgenic models of Huntington's disease
    Sathasivam, K
    Hobbs, C
    Mangiarini, L
    Mahal, A
    Turmaine, M
    Doherty, P
    Davies, SW
    Bates, GP
    [J]. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 1999, 354 (1386) : 963 - 969
  • [9] Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease
    Cha, JHJ
    Frey, AS
    Alsdorf, SA
    Kerner, JA
    Kosinski, CM
    Mangiarini, L
    Penney, JB
    Davies, SW
    Bates, GP
    Young, AB
    [J]. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 1999, 354 (1386) : 981 - 989
  • [10] Transcriptome analysis in two transgenic mouse models for Huntington's disease.
    Kotliarova, SE
    Uchikawa, C
    Kotliarov, YV
    Kamide, Y
    Oyama, F
    Nukina, N
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (04) : 547 - 547
12345